MedTrace Logo

Gadobutrol Magnevist-controlled Body Study

NCT01050829 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 370

Last updated 2014-12-30

No results posted yet for this study

Summary

The purpose of the study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the body/extremities regions. The results of the MRI with gadobutrol injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with Magnevist.

Conditions

  • Magnetic Resonance Imaging

Interventions

DRUG

Gadobutrol (Gadovist, BAY86-4875)

Single administration at a dose of 0.1 mmol/kg

DRUG

Gadopentetate Dimeglumine (Magnevist, BAY86-4882)

Single administration at a dose of 0.1 mmol/kg

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • China
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01050829 on ClinicalTrials.gov